BMS-995

BMS-995 is an early-stage pharmaceutical candidate being developed by Bristol Myers Squibb. It is a novel, oral small molecule inhibitor of Programmed Death-Ligand 1 (PD-L1). Unlike traditional monoclonal antibodies that target the PD-1/PD-L1 pathway via intravenous infusion, BMS-995 is designed for oral administration, potentially offering greater convenience and flexibility in dosing. The drug is part of a broad strategic partnership established in May 2024 between Bristol Myers Squibb and Hengrui Pharmaceuticals, which involves the co-development of 13 early-stage programs across oncology, immunology, and metabolic diseases. BMS-995 is primarily being investigated for the treatment of solid tumors, aiming to restore the immune system's ability to detect and destroy cancer cells by blocking the inhibitory interaction between PD-L1 on tumor cells and PD-1 on T-cells.